Genetic and epigenetic mechanisms are the baseline of cancer initiation, progression and prognosis. Liver cancer can be the result of viral infections, metabolic disorder, genetic variation/mutation and epigenetic deregulation. Among those phenomena evidence of oncosuppressor gene silencing like p53 and TRAIL represent the major class of liver cancer patients. Aim of the project is the re-activation of silenced apoptotic pathway in liver cancer models, plasmidic gene delivery and epigenetic treatment.
A genic and epigenetic combination therapy for liver cancer / Rinaldi, L.; Franci, G; Folliero, V; Palomba, L; Isticato, R; Zannella, C; di Francia, R; De Sio, I; Morelli, G; Lastoria, S; Altucci, L; Pedone, C; Ascione, A; Adinolfi, Le; Galdiero, M. - 49:1(2017), pp. 43-44. (Intervento presentato al convegno Italian Association for the Study of the Liver – Annual Meeting tenutosi a Rome, Italy nel February 23rd–24th, 2017) [10.1016/j.dld.2017.01.090].
A genic and epigenetic combination therapy for liver cancer
Folliero, V;Isticato, RInvestigation
;
2017
Abstract
Genetic and epigenetic mechanisms are the baseline of cancer initiation, progression and prognosis. Liver cancer can be the result of viral infections, metabolic disorder, genetic variation/mutation and epigenetic deregulation. Among those phenomena evidence of oncosuppressor gene silencing like p53 and TRAIL represent the major class of liver cancer patients. Aim of the project is the re-activation of silenced apoptotic pathway in liver cancer models, plasmidic gene delivery and epigenetic treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
